Press "Enter" to skip to content

AstraZeneca starts new COVID-19 prevention trials of antibody cocktail


AstraZeneca has started late-stage trials of an experimental long-acting monoclonal antibody combination drug it hopes could be used as a so-called prophylactic to prevent COVID-19 infection in at-risk people for up to 12 months.

Source link

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *